Frontlight ResearchEarly access
CompletedPhase 4
A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery
Key facts
- Who runs it
- Ocumension Therapeutics (Shanghai) Co., Ltd
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 263 people enrolled
- Started
- 28 Oct 2021
- Ended
- 14 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Dexycu
- Record updated
- 3 September 2025
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Subjects must be able to understand and sign the informed consent form and be able to follow the study procedures
- Male or female subjects over 40 years of age who are scheduled to undergo cataract phacoemulsification surgery combined with intraocular lens implantation
Who cannot take part
- Have high intraocular pressure, with an IOP(intraocular pressure) of > 21 mmHg in the test eye at screening, regardless of whether receiving anti-glaucoma monotherapy therapy
- Known hypersensitivity to dexamethasone or any component of the Dexycu
- History of intraocular inflammation of any cause in either eye, presence of corneal abnormalities or malnutrition
- Posterior capsule rupture or lens dislocation, anterior vitreal membrane rupture, vitreous prolapse and intraoperative floppy iris syndrome during cataract surgery
- Other conditions that the investigator considers inappropriate to participate the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.
The 2 groups in the trial
- Study GroupTreatment being tested
Single injection of DEXYCU in the treatment eye after cataract surgery.
Treatment: Dexycu
- Control GroupNo study treatment, for comparison
The clinical routine treatment after cataract surgery was adopted without intervention
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Real-world Study to Evaluate the Efficacy and Safety of 9% Dexamethasone Intraocular Injection for the Treatment of Inflammation Associated With Cataract Surgery
- Record updated
- 3 September 2025